Targets › PPIA
1 program from 1 company in 11 trials: 7 Phase 2, 2 Phase 3, 2 Phase 4; Cardiovascular, Genitourinary, Hematology.
Catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Exerts a strong chemotactic effect on leukocytes partly through activation of one of its membrane receptors BSG/CD147, initiating a signaling cascade that culminates in MAPK/ERK activation. (UniProt, P62937)
Open in Phaseline: the race on PPIA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | Cyclosporine Cyclophilin A modulator | PPIA | Phase 3 | Moderate to Severe Dry Eye; Meibomian Gland Dysfunction (MGD); Alopecia Areata(AA); Primary Autoimmune Hemolytic Anemia … | – |
Moderate to Severe Dry Eye (1) Meibomian Gland Dysfunction (MGD) (1) Alopecia Areata(AA) (1) Primary Autoimmune Hemolytic Anemia (1) Takotsubo Cardiomyopathy (1) Chronic Myeloproliferative Disorders (1) Type 1 Diabetes (1) Nephrotic Syndrome (1) Aplastic Anemia (1) Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (1) Severe Aplastic Anemia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.